GO:0001836 release of cytochrome c from mitochondria: Apoptotic Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001836 describes the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, a key step in apoptotic signaling.
• Cytochrome c release is often mediated by mitochondrial outer membrane permeabilization (MOMP) and can be regulated by BCL-2 family proteins, cardiolipin, and the permeability transition pore.
• Once in the cytosol, cytochrome c binds APAF1 to form the apoptosome, leading to caspase-9 activation and downstream caspase cascade.
• Sublethal cytochrome c release can promote drug tolerance and persister cell formation in cancer, highlighting its role beyond apoptosis.
• Dysregulated cytochrome c release is implicated in cancer, neurodegenerative diseases, and ischemic injury.
• Research tools include CRISPR knockout/knock-in models, live-cell imaging of cytochrome c reporters, and proteomic analysis of apoptosome components.
Description
The release of cytochrome c from mitochondria (GO:0001836) is a pivotal event in the intrinsic apoptotic pathway. Cytochrome c, normally sequestered in the mitochondrial intermembrane space, translocates into the cytosol upon apoptotic stimuli, where it triggers caspase activation and cell death. This process is tightly regulated by BCL-2 family proteins, mitochondrial lipids, and metabolic cues. Understanding the mechanisms and regulation of cytochrome c release is essential for deciphering cell death signaling and developing therapeutic strategies for diseases ranging from cancer to neurodegeneration. Recent studies have also revealed that sublethal cytochrome c release can generate drug-tolerant persister cells, underscoring its broader biological significance.
release of cytochrome c from mitochondria At A Glance
| GO ID | GO:0001836 |
|---|---|
| GO term | release of cytochrome c from mitochondria |
| Ontology | biological_process |
| Synonym | None |
| Major function | Translocation of cytochrome c from mitochondrial intermembrane space to cytosol, initiating caspase activation |
| Related cellular component | Mitochondrial intermembrane space, cytosol |
| Related molecular function | Protein binding (e.g., APAF1 binding) |
| Regulatory proteins | BCL-2 family (BAX, BAK, BCL-2, BCL-xL), cardiolipin |
| Disease relevance | Cancer, neurodegeneration, ischemia-reperfusion injury |
What Is GO:0001836?
GO:0001836 is defined as the process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation. This process is a critical step in mitochondrial outer membrane permeabilization (MOMP) and is often considered a point of no return in apoptosis.
Why Is release of cytochrome c from mitochondria Important in Cell Biology?
Cytochrome c release is a central checkpoint in apoptosis and a key determinant of cell fate. Its dysregulation contributes to tumorigenesis, chemoresistance, and neurodegenerative disorders. Moreover, sublethal release can promote non-lethal outcomes such as drug tolerance, complicating cancer therapy. Thus, understanding its molecular mechanisms offers opportunities for therapeutic intervention.
• Initiates the intrinsic apoptotic pathway by forming the apoptosome with APAF1 and caspase-9.
• Regulated by BCL-2 family proteins, including BAX/BAK pore formation and anti-apoptotic BCL-2/BCL-xL.
• Cardiolipin in the inner mitochondrial membrane facilitates cytochrome c detachment and release.
• Sublethal cytochrome c release can lead to drug-tolerant persister cells in cancer.
• Implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's.
• Plays a role in ischemia-reperfusion injury in heart and brain.
• Arsenic and other toxins can induce cytochrome c release via permeability transition.
• Target for cancer therapy to overcome apoptosis resistance.
• Biomarker for mitochondrial dysfunction and apoptosis in various diseases.
• Model system for studying MOMP and mitochondrial dynamics.
What Happens During release of cytochrome c from mitochondria?
Initiation by apoptotic stimuli
In simple terms: When a cell receives a death signal, certain proteins on the mitochondria get activated.
Apoptotic stimuli such as DNA damage, growth factor withdrawal, or chemotherapeutic agents activate pro-apoptotic BCL-2 family members like BAX and BAK. These proteins undergo conformational changes and oligomerize on the mitochondrial outer membrane, leading to MOMP.
Mitochondrial outer membrane permeabilization (MOMP)
In simple terms: The outer membrane of mitochondria becomes leaky, allowing proteins to escape.
BAX/BAK pores permeabilize the mitochondrial outer membrane, enabling the release of intermembrane space proteins, including cytochrome c. This process is regulated by anti-apoptotic BCL-2 proteins and can be influenced by mitochondrial lipids such as cardiolipin.
Cytochrome c detachment and translocation
In simple terms: Cytochrome c detaches from the inner membrane and moves into the cytosol.
Cytochrome c is normally bound to cardiolipin on the inner mitochondrial membrane. During apoptosis, cardiolipin oxidation or remodeling promotes cytochrome c detachment, allowing it to diffuse through the permeabilized outer membrane into the cytosol.
Apoptosome formation and caspase activation
In simple terms: In the cytosol, cytochrome c helps assemble a death machine that activates caspases.
Cytosolic cytochrome c binds to APAF1, inducing its oligomerization into the apoptosome. The apoptosome recruits and activates caspase-9, which then cleaves effector caspases-3 and -7, leading to cell death.
Key Genes Involved in GO:0001836 release of cytochrome c from mitochondria
The following genes and proteins are key regulators or effectors of cytochrome c release from mitochondria.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYCS | Cytochrome c, electron carrier and apoptotic trigger | Knockout lethal; point mutations affect apoptosis and respiration |
| BAX | Pro-apoptotic BCL-2 family member, forms pores in MOMP | Knockout reduces cytochrome c release; overexpression induces apoptosis |
| BAK | Pro-apoptotic BCL-2 family member, cooperates with BAX | Double knockout with BAX blocks MOMP |
| BCL2 | Anti-apoptotic, inhibits BAX/BAK | Overexpression blocks cytochrome c release and apoptosis |
| BCL2L1 | Anti-apoptotic (BCL-xL), inhibits MOMP | Overexpression protects against apoptosis |
| APAF1 | Forms apoptosome with cytochrome c, activates caspase-9 | Knockout abolishes caspase-9 activation |
| CASP9 | Initiator caspase activated by apoptosome | Knockout reduces apoptosis |
| CASP3 | Effector caspase, executes apoptosis | Knockout blocks apoptosis |
| CASP7 | Effector caspase, amplifies caspase cascade | Knockout affects apoptosis in some cell types |
| DIABLO | SMAC, promotes apoptosis by inhibiting IAPs | Released with cytochrome c; knockout affects apoptosis |
| ENDOG | Endonuclease G, released during apoptosis | Knockout affects DNA fragmentation |
| AIFM1 | Apoptosis-inducing factor, released during apoptosis | Knockout affects caspase-independent death |
| TP53 | Tumor suppressor, activates BAX/BAK | Knockout reduces cytochrome c release in response to DNA damage |
| BID | BH3-only protein, activates BAX/BAK | Knockout reduces MOMP in some contexts |
| BIM | BH3-only protein, activates BAX/BAK | Knockout reduces apoptosis in lymphocytes |
| PUMA | BH3-only protein, activates BAX/BAK | Knockout reduces apoptosis in response to p53 |
| NOXA | BH3-only protein, sensitizes to apoptosis | Knockout affects apoptosis in some cell types |
| MCL1 | Anti-apoptotic BCL-2 family member | Knockout induces apoptosis; overexpression blocks MOMP |
How Is release of cytochrome c from mitochondria Regulated?
Cytochrome c release is regulated by the balance of pro- and anti-apoptotic BCL-2 family proteins, post-translational modifications (e.g., phosphorylation of BAX/BCL-2), and mitochondrial dynamics. Cardiolipin oxidation and mitochondrial permeability transition also modulate release. Additionally, sublethal release can be regulated by cellular stress and metabolic state, leading to drug tolerance.
release of cytochrome c from mitochondria and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCL2 | Cancer (lymphoma, leukemia) | Overexpression in cancer cell lines; KO in mice |
| BAX | Cancer (colorectal, breast) | KO in cancer cell lines; point mutations |
| CYCS | Neurodegeneration, cancer | Knock-in of apoptosis-deficient mutants |
| APAF1 | Cancer, developmental disorders | KO in cell lines; knock-in of patient mutations |
| CASP9 | Cancer, autoimmune diseases | KO in cell lines; overexpression |
Cancer
Evasion of apoptosis is a hallmark of cancer. Overexpression of anti-apoptotic BCL-2 proteins or loss of BAX/BAK prevents cytochrome c release, contributing to chemoresistance. Conversely, sublethal cytochrome c release can generate drug-tolerant persister cells, which may lead to relapse.
Neurodegenerative diseases
In Alzheimer's and Parkinson's diseases, aberrant cytochrome c release from neuronal mitochondria contributes to synaptic loss and neuronal death. Targeting this pathway is a potential therapeutic strategy.
Ischemia-reperfusion injury
During stroke or myocardial infarction, reperfusion triggers cytochrome c release, exacerbating tissue damage. Inhibiting MOMP or caspase activation may reduce injury.
From release of cytochrome c from mitochondria-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate cytochrome c release? | CRISPR knockout of gene X in HeLa or MEF cells, followed by cytochrome c release assay |
| Does mutation Y affect cytochrome c binding to APAF1? | Point mutation knock-in of CYCS or APAF1, followed by apoptosome formation assay |
| Can we visualize cytochrome c release in real time? | Knock-in of fluorescently tagged cytochrome c (e.g., GFP-CYCS) in cells |
| Does overexpression of BCL-2 block cytochrome c release? | Overexpression of BCL-2 in cancer cell lines, followed by apoptosis induction |
| What is the role of cardiolipin in cytochrome c release? | Knockout of cardiolipin synthase (CRLS1) in cells, followed by cytochrome c release assay |
| Can we screen for modulators of cytochrome c release? | CRISPR library screening with a cytochrome c release reporter |
How to Study the release of cytochrome c from mitochondria Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell imaging | Real-time cytochrome c release | Dynamics of apoptosis in single cells |
| Subcellular fractionation | Cytochrome c in cytosol vs. mitochondria | Quantification of release |
| Immunoprecipitation | Apoptosome components | Detection of APAF1-caspase-9 interaction |
| CRISPR knockout | Gene function in release | Identify essential regulators |
| CRISPR activation | Gene overexpression effects | Screen for suppressors of release |
| Proteomics | Cytosolic proteins released | Global analysis of MOMP |
| Flow cytometry | Cytochrome c release in populations | High-throughput drug screening |
Live-cell imaging of cytochrome c release
Fluorescently tagged cytochrome c (e.g., GFP-CYCS) allows real-time monitoring of release dynamics upon apoptotic stimuli. This method reveals kinetics and subcellular localization.
Subcellular fractionation and Western blot
Separation of mitochondrial and cytosolic fractions followed by immunoblotting for cytochrome c is a classic method to quantify release. It is often used to validate apoptosis induction.
Apoptosome formation assays
Immunoprecipitation of APAF1 or caspase-9 from cytosolic extracts can detect apoptosome assembly. This measures downstream events of cytochrome c release.
CRISPR screening for regulators
Genome-wide CRISPR knockout or activation screens coupled with a cytochrome c release reporter can identify novel regulators of MOMP and apoptosis.
How CRISPR Can Be Used to Study GO:0001836 release of cytochrome c from mitochondria
Knockout
CRISPR knockout of genes such as BAX, BAK, or CYCS can abolish or reduce cytochrome c release, providing causal evidence for their roles. Knockout cell lines are valuable for studying apoptosis resistance.
Point Mutation
Point mutations in CYCS or APAF1 can disrupt cytochrome c binding or apoptosome formation. Knock-in of such mutations allows precise structure-function analysis.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) on CYCS enables live-cell imaging of release. Knock-in of disease-associated mutations can model pathological conditions.
Overexpression
Overexpression of anti-apoptotic BCL-2 or BCL-xL blocks cytochrome c release, while overexpression of BAX/BAK induces it. These models are used to study apoptosis regulation and drug resistance.
How EDITGENE Supports release of cytochrome c from mitochondria Research
Researchers studying release of cytochrome c from mitochondria-related genes often need to determine whether a candidate gene is causally involved in the process, and to dissect its mechanism of action. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for release of cytochrome c from mitochondria research.
Frequently Asked Questions About release of cytochrome c from mitochondria
What is GO:0001836?
GO:0001836 is the Gene Ontology term for the release of cytochrome c from mitochondria, a key step in apoptosis where cytochrome c moves from the mitochondrial intermembrane space to the cytosol.
What genes are involved in release of cytochrome c from mitochondria?
Key genes include CYCS, BAX, BAK, BCL2, APAF1, and CASP9, among others.
How is cytochrome c release regulated?
It is regulated by BCL-2 family proteins, cardiolipin, and mitochondrial permeability transition.
What happens after cytochrome c is released?
Cytochrome c binds APAF1 to form the apoptosome, activating caspase-9 and downstream caspases.
Why is cytochrome c release important in cancer?
Cancer cells often evade apoptosis by blocking cytochrome c release, leading to chemoresistance.
Can sublethal cytochrome c release affect drug response?
Yes, sublethal release can generate drug-tolerant persister cells, contributing to therapy failure.
What methods are used to study cytochrome c release?
Common methods include live-cell imaging, subcellular fractionation, and apoptosome assays.
How can CRISPR help study cytochrome c release?
CRISPR knockout, knock-in, and screening can identify and characterize regulators of the process.
Is cytochrome c release involved in neurodegeneration?
Yes, aberrant release contributes to neuronal death in diseases like Alzheimer's and Parkinson's.
What is the role of cardiolipin in cytochrome c release?
Cardiolipin facilitates cytochrome c detachment from the inner membrane, promoting its release.
Conclusion
Cytochrome c release from mitochondria (GO:0001836) is a central event in apoptosis and a critical regulator of cell fate. Its dysregulation is implicated in cancer, neurodegeneration, and ischemia-reperfusion injury. Advances in CRISPR-based models and imaging techniques continue to unravel its mechanisms, offering new therapeutic opportunities. EDITGENE supports researchers with tailored CRISPR solutions to study this process in depth.
References
- 1. Kalkavan H et al.. 2022. Sublethal cytochrome c release generates drug-tolerant persister cells.. Cell 185(18):3356-3374.e22 PMID: 36055199
- 2. Garrido C et al.. 2006. Mechanisms of cytochrome c release from mitochondria.. Cell Death Differ 13(9):1423-33 PMID: 16676004
- 3. Gogvadze V et al.. 2006. Multiple pathways of cytochrome c release from mitochondria in apoptosis.. Biochim Biophys Acta 1757(5-6):639-47 PMID: 16678785
- 4. Bustamante J et al.. 2005. Arsenic stimulates release of cytochrome c from isolated mitochondria via induction of mitochondrial permeability transition.. Toxicol Appl Pharmacol 207(2 Suppl):110-6 PMID: 15979664
- 5. Ott M et al.. 2007. Role of cardiolipin in cytochrome c release from mitochondria.. Cell Death Differ 14(7):1243-7 PMID: 17431425
- 6. Zhang M et al.. 2017. Release of Cytochrome C from Bax Pores at the Mitochondrial Membrane.. Sci Rep 7(1):2635 PMID: 28572603
- 7. Zhou Z et al.. 2024. Diverse functions of cytochrome c in cell death and disease.. Cell Death Differ 31(4):387-404 PMID: 38521844
- 8. Jemmerson R et al.. 2005. Cytochrome C release from CNS mitochondria and potential for clinical intervention in apoptosis-mediated CNS diseases.. Antioxid Redox Signal 7(9-10):1158-72 PMID: 16115019
